EMA to Expand Scope of Transparency Policy to Cover Corporate Documents

The EMA is considering broadening the scope of its transparency policy to include corporate documents held by the agency.

The EMA is proposing to grant public access to certain corporate documents. The current policy only allows the EMA to release scientific documents.

The revision clarifies what the agency considers a releasable and non-releasable document. For example, documents on a drug approval will not be released until after the EMA makes a final determination on the therapy. Comments on the revisions are due on May 18.